Myriad Genetics posts Q3 earnings beat and lifts full‑year revenue outlook
Myriad Genetics reported third‑quarter 2026 revenue of $202.7 million, surpassing estimates by about 6 %. Adjusted earnings were a loss of $0.11 per share, beating consensus by roughly $0.09. The company raised its full‑year 2026 revenue guidance to a range of $780 million‑$790 million, with a new midpoint of $785 million. Management said the outlook reflects stronger‑than‑expected test volumes and expects margin improvement after a recent divestiture.
Why it matters
The higher revenue guidance signals a more optimistic sales trajectory, which could support the stock price and influence investor expectations for 2026 performance (the company says the raise reflects Q3 outperformance).
Key facts
- 1Q3 2026 revenue was $202.7 million. finance.yahoo.com
- 2Adjusted EPS for Q3 2026 was a loss of $0.11 per share. finance.yahoo.com
- 3Revenue beat analysts' estimates by 6.1 %. finance.yahoo.com
- 4Full‑year 2026 revenue guidance was updated to $780 million‑$790 million. finance.yahoo.com
- 5The midpoint of the guidance was raised to $785 million. finance.yahoo.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.